EC
| |
Euclidean Capital LLC13F | |
| Euclidean Capital LLC | |
| Last update 2025-05-15 | 11 Stocks (0 new) |
| Value $266.00 Mil | Turnover 22 % |
Euclidean Capital LLC Top Holdings of 2025-03-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
INDA | iShares MSCI India ETF | 2,425,144 | 124,846.4 | 0% | 46.910 | 0% | 1.430 | +9.01% | +5.98% | 10,119.6 | ||
VEU | Vanguard FTSE All-World ex-US ETF | 1,991,884 | 120,827.7 | +96.55% | 45.400 | +22.30% | 0.320 | +13.88% | +18.90% | 42,344.4 | ||
FHTX | Foghorn Therapeutics Inc | 1,573,761 | 5,744.2 | 0% | 2.160 | 0% | 2.820 | +62.86% | +8.69% | 286.0 | Biotechnology | |
ORIC | ORIC Pharmaceuticals Inc | 989,410 | 5,520.9 | 0% | 2.070 | 0% | 1.390 | +105.32% | +33.83% | 920.4 | Biotechnology | |
PMVP | PMV Pharmaceuticals Inc | 2,627,643 | 2,864.1 | 0% | 1.080 | 0% | 5.060 | +19.60% | -21.19% | 61.8 | Biotechnology | |
SPY | SPDR S&P 500 ETF Trust | 4,104 | 2,295.7 | -99.54% | 0.860 | -70.97% | 0.000 | +16.86% | +7.34% | 643,153.0 | ||
ALEC | Alector Inc | 1,307,858 | 1,608.7 | 0% | 0.600 | 0% | 1.310 | +38.53% | -20.11% | 151.0 | Biotechnology | |
SRZN | Surrozen Inc | 87,696 | 1,022.5 | 0% | 0.380 | 0% | 1.030 | -28.79% | -41.74% | 71.6 | Biotechnology | |
RAPT | RAPT Therapeutics Inc | 82,237 | 802.6 | 0% | 0.300 | 0% | 0.500 | -9.35% | -36.31% | 133.1 | Biotechnology | |
TNYA | Tenaya Therapeutics Inc | 1,015,705 | 579.0 | 0% | 0.220 | 0% | 0.620 | +17.67% | -57.21% | 99.5 | Biotechnology |
Euclidean Capital LLC's Historical Top Holdings Breakdowns
Euclidean Capital LLC's Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
SPY | SPDR S&P 500 ETF Trust | 2025-03-31 | Reduce Reduce | -70.97% | 551.42 ($587.78) 612.93 | $625.34 | 6.39% | Reduce -99.54% | 4,104 | -892,150 | |
VEU | Vanguard FTSE All-World ex-US ETF | 2025-03-31 | Add Add | +22.30% | 56.51 ($60.25) 62.98 | $67.57 | 12.15% | Add 96.55% | 1,991,884 | 978,450 | |
SPY | SPDR S&P 500 ETF Trust | 2024-12-31 | Reduce Reduce | -19.40% | 567.8 ($589.49) 607.81 | $625.34 | 6.08% | Reduce -25.49% | 896,254 | -306,550 | |
VEU | Vanguard FTSE All-World ex-US ETF | 2024-12-31 | Add Add | +3.94% | 57.29 ($60.21) 63.13 | $67.57 | 12.22% | Add 99.65% | 1,013,434 | 505,834 | |
MEHCQ | 23andMe Holding Co | 2024-12-31 | Sold Out Sold Out | -0.40% | 2.83 ($4.29) 7.77 | $4.90 | 14.22% | Sold Out | 0 | -512,156 | |
SPY | SPDR S&P 500 ETF Trust | 2024-09-30 | Add Add | +3.53% | 517.38 ($552.93) 573.76 | $625.34 | 13.10% | Add 4.87% | 1,202,804 | 55,825 | |
VEU | Vanguard FTSE All-World ex-US ETF | 2024-09-30 | New Buy New Buy | +3.53% | 56.47 ($60.22) 63.69 | $67.57 | 12.21% | New holding | 507,600 | 507,600 | |
SPY | S&P 500 ETF TRUST ETF | 2024-06-30 | Add Add | +11.78% | 495.16 ($523.39) 548.49 | $625.34 | 19.48% | Add 17.68% | 1,146,979 | 172,338 | |
GLD | SPDR Gold Shares ETF | 2024-06-30 | Sold Out Sold Out | -11.40% | 207.82 ($216.29) 224.56 | $307.14 | 42.00% | Sold Out | 0 | -432,271 | |
| NGM Unlock Delisted | NGM Biopharmaceuticals Inc | 2024-06-30 | Sold Out Sold Out | -0.20% | 1.54 ($1.55) 1.56 | $1.54 | -0.65% | Sold Out | 0 | -992,168 |
Euclidean Capital LLC Total Holding History ($B)
Euclidean Capital LLC's Asset Allocation
Euclidean Capital LLC Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
Euclidean Capital LLC's Hypothetical Growth since 2025-03-31
Euclidean Capital LLC's Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
Euclidean Capital LLC's Holdings Heat Map
Size field:
Euclidean Capital LLC's Holdings Bubble Chart
Euclidean Capital LLC News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers